FOLFIRI plus bevacizumab as a second-line therapy for metastatic intrahepatic cholangiocarcinoma

AIM: To evaluate the efficacy and tolerance of FOLFIRI plus bevacizumab treatment outcome as second-line treatment for metastatic intrahepatic cholangiocarcinoma. METHODS: Thirteen consecutive patients with metastatic intrahepatic cholangiocarcinoma who were refractory to first-line therapy consisti...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :World J Gastroenterol
Главные авторы: Guion-Dusserre, Jean-Florian, Lorgis, Veronique, Vincent, Julie, Bengrine, Leila, Ghiringhelli, Francois
Формат: Artigo
Язык:Inglês
Опубликовано: Baishideng Publishing Group Inc 2015
Предметы:
Retrospective Study
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4326145/
https://ncbi.nlm.nih.gov/pubmed/25717243
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3748/wjg.v21.i7.2096
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы